A Phase 1 interventional study of JP-1366 and clopidogrel and JP-1366 and aspirin in Drug Drug Interaction (DDI), sponsored by Onconic Therapeutics Inc.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by Onconic Therapeutics Inc. (part of Jeil Pharmaceutical Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban
Onconic Therapeutics Inc. is the lead sponsor of 19 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
JP-1366 and clopidogrel
Drug: JP-1366 and clopidogrel
JP-1366 and aspirin
Drug: JP-1366 and aspirin
JP-1366 and atorvastatin
Drug: JP-1366 and atorvastatin
JP-1366 and apixaban
Drug: JP-1366 and apixaban
Drug pages: Zastaprazan · Clopidogrel
A randomized, open label, multiple-dosing, 6-sequence, 3-period, 3-treatment, crossover design
Drug pages: Zastaprazan · Aspirin
An open-label, multiple-dosing, fixed sequence, 3-period design
Drug pages: Zastaprazan · Atorvastatin
An open-label, multiple-dosing, fixed sequence, 3-period design Period 1: Atorvastatin
Drug pages: Zastaprazan · Apixaban
An open-label, multiple-dosing, fixed sequence, 3-period design
[Part 1] Change in P2Y12 Reaction Unit (PRU) from baseline on day 8
Change in P2Y12 Reaction Unit (PRU)
Time frame: baseline on day 8
[Part 2] Emax of arachidonic acid-induced platelet aggregation
Emax of arachidonic acid-induced platelet aggregation
Time frame: up to 48 hours post-dose on Day 1
[Part 2] AUEC0-24 of arachidonic acid-induced platelet aggregation
AUEC0-24 of arachidonic acid-induced platelet aggregation
Time frame: up to 48 hours post-dose on Day 1
[Part 2] Cmax,ss of JP-1366
Cmax,ss of JP-1366
Time frame: up to 24 hours post-dose on Day 5
[Part 2] AUCτ,ss of JP-1366
AUCτ,ss of JP-1366
Time frame: up to 24 hours post-dose on Day 5
[Part 2] Cmax of Aspirin
Cmax of Aspirin
Time frame: up to 48 hours post-dose on Day 1
[Part 2] AUClast of Aspirin
AUClast of Aspirin
Time frame: up to 48 hours post-dose on Day 1
[Part 3] Cmax,ss of JP-1366
Cmax,ss of JP-1366
Time frame: up to 24 hours post-dose on Day 5
[Part 3] AUCτ,ss of JP-1366
AUCτ,ss of JP-1366
Time frame: up to 24 hours post-dose on Day 5
[Part 3] Cmax,ss of Atorvastatin
Cmax,ss of Atorvastatin
Time frame: up to 24 hours post-dose on Day 5
[Part 3] AUCτ,ss of Atorvastatin
AUCτ,ss of Atorvastatin
Time frame: up to 24 hours post-dose on Day 5
[Part 4] Emax of Anti-Factor Xa activity
Emax of Anti-Factor Xa activity
Time frame: up to 48 hours post-dose on Day 5
[Part 4] AUEC0-12 of Anti-Factor Xa activity
AUEC0-12 of Anti-Factor Xa activity
Time frame: up to 48 hours post-dose on Day 5
[Part 4] Cmax,ss of JP-1366
Cmax,ss of JP-1366
Time frame: up to 24 hours post-dose on Day 5
[Part 4] AUCτ,ss of JP-1366
AUCτ,ss of JP-1366
Time frame: up to 24 hours post-dose on Day 5
[Part 4] Cmax,ss of Apixaban
Cmax,ss of Apixaban
Time frame: up to 12 hours post-dose on Day 5
[Part 4] AUCτ,ss of Apixaban
AUCτ,ss of Apixaban
Time frame: up to 12 hours post-dose on Day 5
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Mar 2026, 4 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zastaprazan · Clopidogrel · Aspirin · Atorvastatin · Apixaban